Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2002 Sep 24:2:23.
doi: 10.1186/1471-2407-2-23.

Erythropoietin, uncertainty principle and cancer related anaemia

Otavio Clark  1 , Jared R Adams, Charles L Bennett, Benjamin Djulbegovic
Affiliations
Meta-Analysis

Erythropoietin, uncertainty principle and cancer related anaemia

Otavio Clark et al. BMC Cancer. .

Abstract

Background: This study was designed to evaluate if erythropoietin (EPO) is effective in the treatment of cancer related anemia, and if its effect remains unchanged when data are analyzed according to various clinical and methodological characteristics of the studies. We also wanted to demonstrate that cumulative meta-analysis (CMA) can be used to resolve uncertainty regarding clinical questions.

Methods: Systematic Review (SR) of the published literature on the role of EPO in cancer-related anemia. A cumulative meta-analysis (CMA) using a conservative approach was performed to determine the point in time when uncertainty about the effect of EPO on transfusion-related outcomes could be considered resolved.

Participants: Patients included in randomized studies that compared EPO versus no therapy or placebo.

Main outcome measures: Number of patients requiring transfusions.

Results: Nineteen trials were included. The pooled results indicated a significant effect of EPO in reducing the number of patients requiring transfusions [odds ratio (OR) = 0.41; 95%CI: 0.33 to 0.5; p < 0.00001;relative risk (RR) = 0.61; 95% CI: 0.54 to 0.68]. The results remain unchanged after the sensitivity analyses were performed according to the various clinical and methodological characteristics of the studies. The heterogeneity was less pronounced when OR was used instead of RR as the measure of the summary point estimate. Analysis according to OR was not heterogeneous, but the pooled RR was highly heterogeneous. A stepwise metaregression analysis did point to the possibility that treatment effect could have been exaggerated by inadequacy in allocation concealment and that larger treatment effects are seen at hb level > 11.5 g/dl. We identified 1995 as the point in time when a statistically significant effect of EPO was demonstrated and after which we considered that uncertainty about EPO efficacy was resolved.

Conclusion: EPO is effective in the treatment of anemia in cancer patients. This could have already been known in 1995 if a CMA had been performed at that time.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Meta-analysis of EPO use in cancer patients n – number of events; N – number of patients; OR – odds ratio; CI – confidence interval.
Figure 2
Figure 2
Sensitivity analysis using OR. Jadad – value according to Jadad's scale [39]; Adequate random – adequate method of randomization described; Ad all conc – adequate method of allocation concealment used; Double blind trials – double blind trials; Ad desc blind – adequate description of methods of blindness; Plan sample size – planning of the sample size; ITT – intention to treat; Malig – malignancies; CDDP – cisplatin; Disease related anaemia – anaemia due to the effects of the cancer; Trea related anaemia – anaemia due to effects of the treatment (chemotherapy and/or radiotherapy) Hb – hemoglobin level; G/dl – grams/ deciliter. N – number, * Carboplatin used
Figure 3
Figure 3
Analysis and sensitivity analysis using RR. (For legends, see fig 2)
Figure 4
Figure 4
Cumulative meta-analysis of EPO trials. N – number
See this image and copyright information in PMC

References

    1. Hoffman R, Banz JRE, Shattil S. Hematology: Basic Principles and Practice. 3. New York: Churchill Livingstone; 2000.
    1. Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, et al. Randomized phase III Trial Evaluating the Role of Erythropoietin in the prevention of Chemotherapy-Induced Anemia. J Clin Oncol. 1997;15:2715–21. - PubMed
    1. Abels R. Erythropoietin for Anemia in Cancer Patients. Eur J Cancer. 1993;29A:S2–S8. - PubMed
    1. Egger M, Smith GD, Altman D. Systematic Reviews in Health Care. 2. London: BMJ Books; 2001. - PMC - PubMed
    1. Aronson N, Seidenfeld J, Piper MA, Flamm C, Hasselblad V. Use of Erythropoietin in Oncology Evidence Report/Technology Assessment n 30 (Prepared by Blue Cross and Blue Shield Association Evidence-based Practice Center under Contract n 290-97-0015) AHRQ Publication N 01-E009 Rockville, MD: Agency for Healthcare Research and Quality. 2001.

Publication types